Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

287.35USD
25 Jul 2016
Change (% chg)

$-0.43 (-0.15%)
Prev Close
$287.78
Open
$287.84
Day's High
$290.58
Day's Low
$285.02
Volume
1,977,714
Avg. Vol
1,859,986
52-wk High
$338.51
52-wk Low
$223.02

BIIB.O

Chart for BIIB.O

About

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA,... (more)

Overall

Beta: 0.93
Market Cap(Mil.): $63,058.57
Shares Outstanding(Mil.): 219.12
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 16.80 36.15 37.05
EPS (TTM): 17.13 -- --
ROI: 23.33 15.11 14.35
ROE: 31.85 16.17 15.56

BRIEF-Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck

* Collaboration focused on qualification and validation of Tau imaging agent developed by Merck, MK-6240

5:28pm EDT

Biogen's profit easily beats Street view; CEO to leave

Biogen Inc on Thursday reported second quarter profit that blew past Wall Street estimates and significantly raised its full-year earnings forecast, while announcing that Chief Executive George Scangos would step down in the coming months once a successor is found.

Jul 21 2016

UPDATE 2-Biogen's profit easily beats Street view; CEO to leave

July 21 Biogen Inc on Thursday reported second quarter profit that blew past Wall Street estimates and significantly raised its full-year earnings forecast, while announcing that Chief Executive George Scangos would step down in the coming months once a successor is found.

Jul 21 2016

Biogen CEO to leave; company plans $5 bln share buyback

July 21 Biogen Inc said on Thursday Chief Executive George Scangos will leave the U.S. drugmaker in the coming months and that its board approved a $5 billion share repurchase program.

Jul 21 2016

BRIEF-Biogen, Sobi to present long-term data on hemophilia drugs at conference

* Biogen and Sobi to showcase long-term efficacy and safety data from extended half-life hemophilia therapies at world federation of hemophilia 2016 world congress Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

Jul 18 2016

BRIEF-Biogen SB5 accepted for review by European Medicines Agency

* Sb5, an adalimumab biosimilar referencing humira, accepted for review by european medicines agency Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

Jul 18 2016

Samsung Bioepis seeks Europe approval for its Humira copy

SEOUL Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.

Jul 17 2016

UPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy

* European Medicines Agency reviewing Samsung Bioepis' application

Jul 17 2016

BRIEF-Biogen and AbbVie's drug approved in EU

* Biogen and AbbVie's once-monthly zinbryta(tm) (daclizumab) approved in European Union for treatment of multiple sclerosis

Jul 05 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.89 -0.14
Pfizer Inc. (PFE.N) $36.78 +0.04
Novartis AG (NOVN.S) CHF82.20 -0.15
Merck & Co., Inc. (MRK.N) $58.56 -0.26
Roche Holding Ltd. (ROG.S) CHF248.80 -1.00
Roche Holding Ltd. (RO.S) CHF250.00 -2.25
Bayer AG (BAYGn.DE) €92.62 +0.55
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.51 --
GlaxoSmithKline plc (GSK.L) 1,657.00p -2.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Wright Reports
$75.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.